1. Home
  2. News
  3. Chimeric Therapeutics Limited
  4. Phase 1B brain cancer clinical trial approved for initiation
More Chimeric Therapeutics Limited news
Chimeric Therapeutics LimitedASX: CHM

Phase 1B brain cancer clinical trial approved for initiation

Apr 25, 2023 at 11:08 PM EDT · Issued by Chimeric Therapeutics Limited

Filed with ASX · Apr 25, 2023 at 11:08 PM EDT · 4 pages · English

On 6ix: 6ix.com/news/phase-1b-brain-cancer-clinical-trial-approved-for-initiation

Chimeric Therapeutics Limited on 6ix

Story so far

  • Positive pre-IND meeting with FDA for Phase 1 CAR T studyMar 21, 2023
  • Exclusive license agreement with CWRU for CORE-NK platformNov 21, 2022
  • Patent received in Japan for CLTX CAR technologyAug 3, 2022

Earlier from Chimeric Therapeutics

  • CHM 1101 GBM Abstract Accepted for ASCO 2023 PresentationApr 3, 2023
  • Positive pre-IND meeting with FDA for Phase 1 CAR T studyMar 20, 2023
  • Fourth dose cohort initiated in CHM 1101 Phase 1 trialMar 2, 2023
  • Appendix 4D and Half Year ReportFeb 28, 2023
  • Chimeric receives $3.06M R&D tax incentiveFeb 14, 2023

Later from Chimeric Therapeutics

  • New CLTX CAR technology patent protection in India & IsraelApr 28, 2023
  • Board & management commit to $1M placement and proposed SPPMay 15, 2023
  • SPP offer documents issued to shareholdersMay 22, 2023
  • Launch of new Phase 1B Glioblastoma clinical trialJun 4, 2023
  • Share purchase plan completedJun 23, 2023
All Chimeric Therapeutics news releases↗

Follow Chimeric Therapeutics into a list and get an email when it puts out news.

Follow Chimeric Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer